K2M GROUP HOLDINGS, INC. (NASDAQ:KTWO) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

0

K2M GROUP HOLDINGS, INC. (NASDAQ:KTWO) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On December 5, 2017, the Board of Directors (the “Board”) of K2M Group Holdings, Inc. (the “Company”) approved an amendment to the Company’s Amended and Restated Bylaws (the “Bylaws”) which provides, in Article II, Section 2.06 of the Bylaws, that in an uncontested election, any director nominee who receives a greater number of votes “withheld” from his or her election than votes “for” his or her election must tender his or her resignation to the Board. The Board shall decide, through a process managed by the Company’s Nominating and Corporate Governance Committee, whether to accept the resignation of the nominee at its next regularly scheduled Board meeting. The Board’s decision with respect to the resignation will be promptly disclosed in a public announcement. An election of directors is a “contested election” if the number of nominees exceeds the number of directors to be elected.

This description is qualified in its entirety by reference to the Bylaws filed herewith as Exhibit 3.1.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits


K2M GROUP HOLDINGS, INC. Exhibit
EX-3.1 2 amendedbylaws1252017.htm EXHIBIT 3.1 Exhibit Exhibit 3.1AMENDED AND RESTATED BYLAWS OF K2M GROUP HOLDINGS,…
To view the full exhibit click here

About K2M GROUP HOLDINGS, INC. (NASDAQ:KTWO)

K2M Group Holdings, Inc. is a medical device company focused on designing, developing and commercializing spine technologies and techniques. The Company’s spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor. The Company is engaged in designing, development and commercialization of products for patients suffering from degenerative spinal conditions. Its products consist of implants, disposables and instruments, which are marketed and sold primarily to hospitals for use by spine surgeons. The Company’s product portfolio contains over 70 product lines that are used in spine surgeries, minimally invasive spine (MIS) and degenerative surgeries. It markets or sells its products in the United States and over 36 other countries. The Company’s technologies include MESA, Rail 4D, Quicket Deformity, CAPRI, SERENGETI, RAVINE, EVEREST, CASCADIA and tifix.

An ad to help with our costs